Navigation Links
Leviticus Cardio Ltd. Completes a Successful Animal Trial for its Wireless Energy System for VADs
Date:5/2/2013

TEL AVIV, Israel, May 2, 2013 /PRNewswire/ --

Leviticus Cardio, a portfolio company of the Mofet Venture Accelerator, owned by the Trendlines Group, recently performed a successful animal surgical trial using its wireless coplanar energy transfer system (CET) for ventricular assist devices (VAD). The surgery was performed at Assaf Harofeh Hospital and produced a 75% full system efficiency rate as compared with 78% efficiency in vitro.

The animal trials were done using the Leviticus CET system and Jarvik Heart VAD. The CET system performed the energy transfer to the animal body and controlled the VAD pump operation.

In vitro lab tests were conducted using several commercial VAD systems of Thoratec, Heartware, Jarvik Heart and Cleveland Heart . In all these tests, the Leviticus CET system was used to transfer the energy and to control the VAD pumping operation using the Leviticus advanced controller.

Leviticus Cardio was selected to present the results of these in vitro and in vivo tests as part of the scientific program in ISHLT 2013 convention held at Montreal.  

VADs are used to extend the lives of thousands of patients suffering from chronic heart failure or waiting for a heart transplant. Today, VAD patients are connected with wires to an external power supply - risking dangerous infections, repeated hospitalizations and severely limiting mobility. Leviticus Cardio's wireless CET system powers the VAD without wires, thereby avoiding the complications associated with today's technologies. In addition, the Leviticus Cardio's system can easily be removed for limited periods of time to give patients complete freedom of movement without any external device attached.

Michael Zilbershlag, Leviticus co-founder and CEO, stated, "This successful trial is a significant milestone in validating our technology and advancing towards commercialization. We are especially fortunate to be working with Prof. Stephan Schueler , M.D., a leading cardiothoracic surgeon in Europe and with the support from VAD manufacturer Jarvik Heart for the procedures."

Prof. Schueler remarked: "This new device allows us to apply the VAD technology to a wider group of patients outside of the transplant patients' group. For them, to have all the advantages of a wireless technology will have a huge impact on their morbidity and even mortality, and quite obviously on their quality of life."


Media relations:   Efrat Kaduri , Ofir Shpigel Media and Public Relations, +972-4-9535030


'/>"/>
SOURCE Leviticus Cardio Ltd
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Le cardio pourrait être la clé pour soigner le cancer
2. Emory Cardiologists Arshed Quyyumi And Javed Butler Join Stemedica Cardiology Division Scientific Advisory Board
3. ChanTest Introduces the CardioChannelGram™ and SaVety Assessment
4. Cardiovascular Drug Delivery - Technologies, Markets and Companies - 2013 Report
5. Douglas Harrington, MD Addresses Select Group Of Physicians Regarding Latest Advances In Cardiovascular Risk Assessment
6. CardioWise™ Welcomes Geoffrey Dalbow as Chief Technology Officer
7. Infinata’s BioPharm Insight Gears Up for the 2013 American College of Cardiology Meeting with the Release of its Cardiovascular Diseases Report
8. Stephen Epstein, MD To Head Scientific & Medical Advisory Board For Stemedica’s Cardiology Division
9. Interventional Cardiology Devices Market is Expected to Reach USD 25.2 Billion Globally in 2018: Transparency Market Research
10. Cardiometabolic Health Congress Expert Faculty Evaluate the Clinical Implications of Newly FDA-Approved Treatment for Homozygous Familial Hypercholesterolemia
11. Cardium Announces Patent Award For Rights To Cardiovascular Gene Therapy For The Treatment Of Heart Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Tbilisi, Georgia (PRWEB) , ... October 11, 2017 , ... ... disaster, taking the lives of over 5.5 million people each year. Especially those living ... the greenovative startup Treepex - based in one of the most pollution-affected countries globally ...
(Date:10/10/2017)... Angeles, CA (PRWEB) , ... ... ... Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, ... uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in ...
(Date:10/10/2017)... CRUZ, Calif. , Oct. 10, 2017 ... grant from the NIH to develop RealSeq®-SC (Single Cell), ... kit for profiling small RNAs (including microRNAs) from single ... Analysis Program highlights the need to accelerate development of ... "New techniques for measuring ...
(Date:10/9/2017)... ... October 09, 2017 , ... The award-winning American Farmer television series ... 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. , With global population ... challenge of how to continue to feed a growing nation. At the same time, ...
Breaking Biology Technology:
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/5/2017)... 4, 2017 KEY FINDINGS The ... at a CAGR of 25.76% during the forecast period ... primary factor for the growth of the stem cell ... MARKET INSIGHTS The global stem cell market ... and geography. The stem cell market of the product ...
(Date:3/30/2017)... LOS ANGELES , March 30, 2017  On ... Hack the Genome hackathon at ... This exciting two-day competition will focus on developing health ... experience. Hack the Genome is ... has been tremendous. The world,s largest companies in the ...
Breaking Biology News(10 mins):